Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

• Published in: Diabetes care Vol. 44; no. 8; pp. 1894 - 1897
• Main Authors: Persson, Frederik, Rossing, Peter, Vart, Priya, Chertow, Glenn M., Hou, Fan Fan, Jongs, Niels, McMurray, John J.V., Correa-Rotter, Ricardo, Bajaj, Harpreet S., Stefansson, Bergur V., Toto, Robert D., Langkilde, Anna Maria, Wheeler, David C., Heerspink, Hiddo J.L.
• Format: Journal Article
• Language: English
• Published: Alexandria American Diabetes Association 01.08.2021
• Subjects: Albumins; Antidiabetics; Creatinine; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetic ketoacidosis; End-stage renal disease; Epidermal growth factor receptors; Glomerular filtration rate; Glucose; Health risks; Hypoglycemia; Ketoacidosis; Kidney diseases; Kidneys; Novel Communications in Diabetes; Research design; Risk management

OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular outcomes with dapagliflozin versus placebo in participants with chronic kidney disease (CKD) with and without diabetes. We compared outc...